. Central biogenic amine neurons such as those containing serotonin, norepinephrine (NE), histamine, and acetylcholine have been shown to display robust changes in neuronal activity across the sleep-wake states and are postulated to play a prominent role in the regulation of sleep and W in general and in both behavioral and electroencephalographic (EEG) arousal. In contrast, dopamine (DA) neurons, which have been reported to exhibit a limited alteration in discharge rates across the sleep-wake cycle, have been generally thought to play a minor role in overall behavioral state control. 1 Early pharmacologic studies on DA have demonstrated, however, that DA is important in maintaining behavioral arousal. Indeed, injections of DA directly into the brain increase motor activity in animals. 2 Electrolytic lesioning of DA-containing neurons in the ventral tegmental area and substantia nigra causes a lack of behavioral responsiveness and motor akinesia. 3 A similar behavioral effect is obtained after a selective destruction of substantia nigra neurons by 6-hydroxydopamine, though EEG arousal is preserved in this case. 4 A high DA content is observed during W, 5 and the turnover of DA decreases during the transition from W to slow-wave sleep (SWS). 6 The DA neurons of the substantia nigra and ventral tegmental area exhibit an increase in firing rate in association with large bodily movements. 7-9 It has been recently shown that presynaptically acting dopaminomimetics, such as inhibitors of DA transporters or DA-releasing agents, increase W but have limited effects on paradoxical sleep (PS) generation. 10, 11 These observations support the idea that the DA system and especially the nigrostriatal DA system is important in behavioral arousal but are not essential for EEG arousal. Several lines of experimental and clinical data suggest that other DA systems such as the mesolimbic, mesocortical, or diencephalospinal systems might also be involved in behavioral state control. The DA agonist apomorphine at low doses, for example, significantly decreases the latency to sleep and increases the total amount of sleep. 12, 13 Patients with Parkinson disease experience severe sleep disorders, 14 and sleep disruption and excessive daytime sleepiness are common complaints in patients treated with antiparkinsonian dopaminergic compounds such as L-dopa and DA-receptor agonists. 15, 16 We have recently found that microdialysis application of NE, epinephrine (E), or DA significantly decreased the amount of PS, also known as rapid eye movement (REM) sleep, when applied to a mediodorsal pontine tegmental region, designated peri-locus coeruleus α (peri-LC α). 17 In the present study, we sought to determine the sites of PS inhibition by DA within the mesopontine structures, which play an important role in the regulation of both W and PS, 1 and the receptor subtypes implicated in this DA effect using the reverse microdialysis technique in freely behaving cats.
INTRODUCTION

MANY NEUROTRANSMITTER SYSTEMS ARE INVOLVED IN THE REGULATION OF SLEEP AND WAKEFULNESS (W).
Central biogenic amine neurons such as those containing serotonin, norepinephrine (NE), histamine, and acetylcholine have been shown to display robust changes in neuronal activity across the sleep-wake states and are postulated to play a prominent role in the regulation of sleep and W in general and in both behavioral and electroencephalographic (EEG) arousal. In contrast, dopamine (DA) neurons, which have been reported to exhibit a limited alteration in discharge rates across the sleep-wake cycle, have been generally thought to play a minor role in overall behavioral state control. 1 Early pharmacologic studies on DA have demonstrated, however, that DA is important in maintaining behavioral arousal. Indeed, injections of DA directly into the brain increase motor activity in animals. 2 Electrolytic lesioning of DA-containing neurons in the ventral tegmental area and substantia nigra causes a lack of behavioral responsiveness and motor akinesia. 3 A similar behavioral effect is obtained after a selective destruction of substantia nigra neurons by 6-hydroxydopamine, though EEG arousal is preserved in this case. 4 A high DA content is observed during W, 5 and the turnover of DA decreases during the transition from W to slow-wave sleep (SWS). 6 The DA neurons of the substantia nigra and ventral tegmental area exhibit an increase in firing rate in association with large bodily movements. [7] [8] [9] It has been recently shown that presynaptically acting dopaminomimetics, such as inhibitors of DA transporters or DA-releasing agents, increase W but have limited effects on paradoxical sleep (PS) generation. 10, 11 These observations support the idea that the DA system and especially the nigrostriatal DA system is important in behavioral arousal but are not essential for EEG arousal. Several lines of experimental and clinical data suggest that other DA systems such as the mesolimbic, mesocortical, or diencephalospinal systems might also be involved in behavioral state control. The DA agonist apomorphine at low doses, for example, significantly decreases the latency to sleep and increases the total amount of sleep. 12, 13 Patients with Parkinson disease experience severe sleep disorders, 14 and sleep disruption and excessive daytime sleepiness are common complaints in patients treated with antiparkinsonian dopaminergic compounds such as L-dopa and DA-receptor agonists. 15, 16 We have recently found that microdialysis application of NE, epinephrine (E), or DA significantly decreased the amount of PS, also known as rapid eye movement (REM) sleep, when applied to a mediodorsal pontine tegmental region, designated peri-locus coeruleus α (peri-LC α). 17 In the present study, we sought to determine the sites of PS inhibition by DA within the mesopontine structures, which play an important role in the regulation of both W and PS, 1 and the receptor subtypes implicated in this DA effect using the reverse microdialysis technique in freely behaving cats.
A preliminary report of this work has been published in abstract form. 18 
MATERIALS AND METHODS
Animals and Surgery
Seven adult male and female cats weighing 2.6 to 4.0 kg at the time of surgery were used. These cats were born and bred in our laboratory at Claude Bernard University and were descended from cats obtained from Domaine Saint-Louis, Bray-Lu, France. All procedures were carried out in conformity with the EEC Council Directive 86/609, and every effort was made to minimize any pain and discomfort and the number of animals used. Under deep pentobarbital anesthesia (Nembutal, 25 mg/kg, IV), animals were implanted with standard electrodes for assessment of states of vigilance: cortical and hippocampal electroencephalogram (EEG), electromyogram (EMG), electrooculogram (EOG), and EEG from the dorsal lateral geniculate nucleus for the detection of pontogeniculooccipital (PGO) waves. In addition, a total of 6 guide cannulae (23-gauge) with indwelling stylets were implanted in the brain. Four cannulae were inserted bilaterally with an angle of 52° from the horizontal and their tips lying 5 to 10 mm above the rostral and caudal parts of the peri-LC α, respectively. Two cannulae were inserted vertically with their tips lying 5 mm above the ventrolateral periaqueductal gray (PAG). All animals received antibiotics once on the day after surgery (extencilline, IM) and then once daily (thiamphenicol, orally) for 3 days. After surgery, the cats were housed individually in sound-attenuated and electrically shielded recording chambers, maintained at 24° to 26°C and dimly illuminated from 6:00 AM to midnight. Food and water were available ad libitum. The cats were habituated to the experimental conditions until they displayed normal sleep-wake cycles.
Polygraphic Recordings and Analysis
The animals were connected to a polygraph (GRASS Model 78B, Quincy, Mass, USA) through a slip ring, allowing them to move freely in the recording chambers. The data were digitized using a CED 1401 data processor (Cambridge Electronic Design (CED), Cambridge, UK) at a sampling rate of 128 Hz. Behavioral states were determined by both automated and visual analysis of the EMG, EOG, neocortical, hippocampal, and lateral geniculate EEG (PGO waves) recordings. States of vigilance were scored minute by minute and classified according to standard criteria into 1) W, 2) light SWS (S1), 3) deep SWS (S2), and PS. Power spectra were computed for consecutive 4-second epochs of the EEG data using a Fast Fourier Transform routine and the Spike2 analyzing program, as described previously. 17 
Experimental Protocol
A more detailed account of the reverse microdialysis procedure can be found elsewhere. 17, 19 Briefly, on the day preceding each experimental session, a microdialysis probe (A-L-50-01, Eicom, Kyoto, Japan) was inserted through a guide cannula and left in the brain for 5 to 6 consecutive days. The probe membrane was 1 mm in length and had an external diameter of 0.23 mm. The small size of the membrane permits us to minimize the diffusion of the drug delivered outside the target zone. The perfusate has been reported to diffuse almost exclusively laterally from the membrane for 0.5 to 0.75 mm, 17 and an approximately 10-fold reduction in concentration of drug is found in the surrounding medium outside the membrane over the first hour of perfusion. 20, 21 Drugs were applied on experimental days 2 to 5 in order to avoid any effects of acute tissue damage on the EEG and behavioral states. Polygraphic recordings were started at approximately 9:00 AM and continued for 23 hours. After animal care, the probe was perfused continuously with Ringer's solution. To keep experimental factors constant, drug application began at least 1 hour after a control recording session, which consisted of at least 1 complete sleep-wake cycle, including W, S1, S2, and a PS episode lasting more than 3 minutes. Drugs were applied for 2 consecutive hours, and the perfusate was then switched back to Ringer's solution for 3 to 6 hours to assess recovery. The order of drug application was random. All DA-receptor agonists were applied to the same site. Control experiments were performed once or twice a week by continuously perfusing Ringer's solution. At the end of each experimental session, the probe was removed from the brain, and the cat was allowed to recover for 2 days before the next experimental session. Successive microdialysis probe insertions through the same cannula to more ventral sites were separated by at least 2 weeks. One or a maximum of 3 insertions were made through the same guide cannula. At the end of the experiments, the animals were killed under deep pentobarbital anesthesia, and the position of the dialysis probes determined on neutral-red-stained sections. 17 
Statistical Analysis
The amounts of the different sleep-wake states were expressed in minutes, and the means ± SEM were calculated for the 2 hours of drug application. The data from each experimental group (same drug and same site) were compared with those from paired control recordings using the same animal, site, and experimental period by means of a 2-tailed t-test. In all instances, a P value of less than 0.05 was considered statistically significant. Site dependency of the effect of DA was analyzed by comparing the PS amounts during the 2-hour drug-application period after local application of 5 mM of DA with those after application of Ringer's solution alone (baseline). A change greater than 2 SDs from the mean baseline value was considered significant.
Drugs
The drugs used were 3-hydroxytyramine hydrochloride (DA), (±)-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (SKF-81297), quinelorane dihydrochloride, quinpirole hydrochloride, (±)-7-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (7-OH-DPAT), clonidine hydrochloride, and RX 821002 hydrochloride (all from Sigma RBI, Natick, MA, USA). All drugs were dissolved in Ringer's solution (pH ca. 6.0) just before use and protected from light and heat during the experiment. Drug solutions were adjusted to pH 6.0, if necessary, with 0.5N sodium hydroxide.
RESULTS
The effects of microdialysis application of 5 mM DA on behavioral states were first examined in caudal mesencephalic and rostral pontine structures ( Figure 1A ). As shown in Figure 1A , DA had no significant effect on behavioral states when applied to the PAG, adjacent central tegmental field, cholinergic peribrachial nuclei such as the laterodorsal tegmental nucleus, and cholinergic component of the nucleus tegmenti pedunculopontinus, pars compacta, noradrenergic locus coeruleus (LC) and LC pars α (LCα) or giganto- 
Latency (minutes) 12.9 ± 2.0 26.2 ± 4.9 * 9.7 ± 2.8 11.7 ± 2.8 11.5 ± 1. The values are the mean time or number (± SEM) observed during a 2-hour application into the caudal peri-locus coeruleus α of Ringer's solution (baseline), 5 mM dopamine (DA), 5 mM dopaminergic agonists, 5 mM dopamine + 1 mM RX821002, and 200 µM clonidine (CLO). The number of trials is shown in parentheses. Baseline indicates the mean values from all paired controls. Latency is the time from the beginning of drug infusion (when the drug reached the microdialysis membrane) to the first paradoxical sleep (PS) episode. Duration and number indicate, respectively, the mean duration and number of PS episodes during the 2-hour drug application. The effects were analyzed by a 2-tailed Student's ttest by comparing the experimental values with those of paired controls obtained from the same animal, site, and experimental period. * P < 0.05; ** P < 0.01, compared with paired controls; otherwise, the difference was not statistically significant.
cellular tegmental field. In contrast, a significant decrease in PS was observed when DA was applied to the caudal part of the peri-LCα (L 2.0, P 2.5-4.0,), 17 which contains mainly noncholinergic and nonnoradrenergic descending neurons 17, 22 and is critically implicated in the executive mechanisms of PS generation. 23 In this nucleus, 2 mM and 5 mM injections of DA induced a dose-related decrease in PS without significantly affecting other behavioral states (Figure 2 ). The PS-inhibiting effect of DA resulted from a significant increase in the latency to first PS episode and decrease in the mean duration and number of PS episodes (Table) .
In addition, at the high concentration, DA induced partial or complete lack of muscle atonia during the remaining PS episodes, with EMG activity even increasing during the transition from SWS to PS and the cat occasionally raising its head during these PS episodes (PS without atonia) (Figures 1B and C) . This effect was seen particularly when DA was applied to the most caudal part of the peri-LCα ( Figure 1A 24 In order to determine what receptor types were involved in PS inhibition and induction of PS without atonia by DA application, we first examined the effects of microdialysis application of a D 1 -like receptor agonist (SKF-81297) and 3 agonists of D 2 -like receptors (quinelorane, quinpirole, and 7-OH-DPAT). All agonists were applied at concentrations of 2 or 5 mM to the caudal part of the peri-LCα.
As shown in Figure 3 and summarized in Table, microdialysis application of SKF-81297 had no effect on behavioral states or on PS architecture, such as PS latency, frequency, and duration. In contrast, application of D 2 -like agonists significantly decreased W and increased both S2 and PS (Figure 3) . The most robust W-reducing and S2-increasing effects were seen with quinelorane, regarded as a selective agonist of D 2 receptors (Figures 3 and 4) . During the 2-hour application of 2 mM and 5 mM of quinelorane, the amounts of S2 were 57.7 ± 3.8 and 45.2 ± 4.1 minutes, respectively, which were significantly higher than the paired control values (29.5 ± 2.0 minutes [N = 8] and 27.4 ± 3.4 minutes [N = 7], respectively). Inversely, the amounts of W decreased from 26.0 ± 2.9 or 17.5 ± 5.2 minutes in the control to 5.7 ± 2.3 or 3.4 ± 1.2 minutes, respectively. As illustrated in Figure 4 , quinelorane greatly reduced awakenings and large bodily movements; only short-lasting movements were observed in association with posture changes across the sleep cycle. Similar W-reducing and S2-promoting effects were seen with application of quinpirole, a D 2 /D 3 -receptor agonist, or 7-OH-DPAT, a D 3 -preferring DA-receptor agonist. With these DA-receptor agonists, a significant increase in PS was further noted. This increase in PS was mainly due to a significant increase in the number of PS episodes (Table) . The rank order of potency of these DA-receptor agonists in PS facilitation was 7-OH-DPAT > quinpirole >quinelorane. The amounts of Small and large closed circles indicate the sites at which the amount of PS during 2-hour application of DA was reduced to less than 2 SD from the mean baseline value. Large closed circles indicate the site at which DA induced PS without atonia. Abbreviations: BC, brachium conjunctivum; FTC, central tegmental field; FTG, gigantocellular tegmental field; LC, locus coeruleus; LCα, locus coeruleus α; LDT, laterodorsal tegmental nucleus; PAG, periaqueductal gray; peri-LCα, peri-locus coeruleus α; TPC, cholinergic component of the nucleus tegmenti pedunculopontinus, pars compacta. PS during the 2-hour application of 2 mM and 5 mM 7-OH-DPAT increased from 21.5 ± 1.1 minutes (N = 8) and 21.5 ± 3.0 minutes (N = 6) in the control to 31.7 ± 2.8 minutes and 35.0 ± 2.1 minutes, respectively. No episodes of PS without atonia were seen with the application of DA agonists even at the high concentration. These results indicate that the PS-inhibiting effects of DA observed in the caudal peri-LCα are not mediated by DA receptors. Pharmacologic studies demonstrated that DA is also a potent agonist for α 2 adrenoceptors. 25 We, therefore, examined the hypothesis that DA inhibits PS by acting through α 2 adrenoceptors. In support of this, we found that the PS-inhibiting effects of 5 mM DA were completely blocked when applied simultaneously with 1 mM RX821002, a selective antagonist of α 2 adrenoceptors that is devoid of interactions with the imidazolinebinding site. The amount of PS during the 2-hour drug application was 21.8 ± 1.6 minutes, the value being very close to the baseline (Figure 2) . The simultaneous application of RX821002 also completely restored PS architecture and resulted in a nonsignificant increase in S2 (Table and Figure 2 ). Furthermore, application of clonidine, an α 2 -selective adrenoceptor agonist, inhibited PS in a dose-dependent manner (Figure 2A ) and induced PS without atonia at the high concentration. The effects of 200 µM of clonidine on PS amount and PS architecture were quite similar to those seen with 5 mM of DA (Figure 2 and Table) . These results strongly suggest that the PS-inhibiting effects of DA observed in the caudal peri-LCα are not mediated by DA receptors, but by α 2 adrenoceptors.
DISCUSSION
The present study shows that DA inhibits PS and induces PS without atonia only when applied to the caudal peri-LCα within the caudal mesencephalic and rostral pontine structures. The PS-inhibiting effects of DA appear to be mediated by α 2 adrenoceptors. When applied to the same region, D 2 -like DA-receptor agonists induce a significant decrease in W and an increase in both S2 and PS.
Five DA-receptor subtypes have been identified and are classically divided into 2 classes: D 1 -like receptors (D 1 and D 5 ) that couple to the G protein Gs and activate adenylyl cyclase and D 2 -like receptors (D 2 , D 3 , and D 4 ) that either couple to the G protein Gi and inhibit adenylyl cyclase or are not linked to adenylyl cyclase. 24, 26, 27 The DA-receptor agonists used in the present study display a good selectivity for the 2 classes of DA receptors (D 1 -like vs D 2 -like) but show only little selectivity for the different subtypes of each class. 24 In the present study, DAreceptor agonists were applied at relatively high concentrations. It seems unlikely, therefore, that the inability of the DA-receptor agonists to mimic the PS-inhibiting effect of DA is ascribed to their lack of potency to one of the DA receptors. The effects of DA were mimicked by the α 2 -adrenergic agonist clonidine and completely blocked by the α 2 -adrenergic antagonist RX821002. It seems, therefore, that DA inhibits PS in the caudal peri-LCα via α 2 adrenoceptors. The importance of α 2 adrenoceptors in the inhibitory mechanisms of PS generation in the pons has been demonstrated previously. [28] [29] [30] Early pharmacologic studies have also demonstrated DA activation of α 2 adrenoceptors 25 : DA has been found to inhibit NE release in peripheral nerve terminals by acting via presynap- tic α 2 adrenoceptors with a potency equal to 31 or twice less 32 than that of NE.
The sites of atonia suppression by DA revealed in the present study correspond exactly to those at which unilateral microdialysis application of NE, E, or 4-DAMP (a M 1 /M 3 muscarinic receptor antagonist) produces PS without atonia. 17, 33 The present report thus further substantiates the views that the caudal peri-LCα is of a particular importance for the generation of atonia during PS 34 and that catecholaminergic drugs exert an important inhibitory action in the mechanisms of atonia and cataplexy in narcolepsy. 35 We found that application of D 2 -like DA agonists in the caudal peri-LCα significantly decreased W and increased both S2 and PS, suggesting an important role played by the DA system in the control of sleepwake states. These results were somewhat surprising because application of DA alone did not have significant W-reducing and sleep-promoting effects when applied to the same region. This may be that the activation of α 2 adrenoceptors by DA masks effects of DA-mediated through own receptors. Indeed, a nonsignificant increase in S2 was seen when the PSand atonia-inhibiting effects of DA are blocked with co-application of the α 2 -adrenoceptor antagonist RX821002. The present data from the microdialysis application of selective D 2 -like agonists to the peri-LCα in the cat are very similar to those observed after systemic administration of low doses of the nonselective DA-receptor agonist apomorphine 12, 13 or the selective D 2 -like agonist quinpirole 36 in the rat: decreases in both W and motor behavior and increases in both SWS and PS. This increase in PS might be secondary to increased amounts of SWS. In support of this assumption, the increase in PS was mainly due to a significant increase in the number of PS episodes, with the duration of PS episodes remaining virtually unchanged. However, the D 2 -like agonists used in the present study did not have similar effects on W, SWS, and PS. For example, the D 2 -selective DA-receptor agonist quinelorane produced a marked decrease in W and an increase in SWS but had little effect on PS generation. In contrast, the D 2 /D 3 agonist quinpirole significantly increased PS and SWS but did not significantly decrease W. Furthermore, the D 3 -preferring agonist 7-OH-DPAT induced a robust increase in PS but had relatively little effect on SWS. These results suggest that the effects of D 2 -like agonists on SWS, W, and PS might be dissociated and ascribed to activation of different D 2 -like receptor subtypes.
The D 2 -like receptors have been found at both presynaptic and postsynaptic sites. 24 The main postsynaptic action of D 2 -like receptors seems to be an increase in potassium conductance resulting in hyperpolarization of the cell. 37, 38 Presynaptic D 2 -like receptors have been shown to inhibit glutamatergic and GABAergic transmission as well. [39] [40] [41] [42] The present finding that D 2 receptor agonists never decreased PS when applied to the peri-LCα suggests that the W-reducing and sleep-promoting effects of the DA agonists are not mediated by their direct postsynaptic inhibitory actions on the peri-LCα neurons that play a critical role in the executive mechanisms of PS. 23 The DA-receptor agonists might induce the sleep-enhancing effects by inhibiting neurons located in or in close proximity to the caudal peri-LCα, such as noradrenergic neurons in the LC and LCα, located just dorsal or lateral to the peri-LCα. This might be achieved through either a direct postsynaptic inhibition or a mechanism of disfacilitation due to inhibition of glutamatergic transmission. These noradrenergic neurons are supposed to play an important role in the maintenance of behavioral and EEG arousal via ascending projections to telediencephalic structures, 1 as well as in the inhibitory mechanisms of PS generation via direct inhibitory actions on PS-on neurons. 23, 43 The effects on behavioral states of application of DA-receptor agonists to the LC complex remain to be determined. Iontophoretic application of bicuculline, a potent GABA A -receptor antagonist, has been shown to excite PS-on neurons, 44 while local injection or microdialysis application of bicuculline has been reported to increase PS when applied to the peri-LCα region, 23, 45 suggesting the presence of tonic GABAergic inhibitory control on the pontine PS executive neurons. The PS-enhancing effect of D 2 -like agonists, therefore, might also be attributed to disinhibition of PS-on neurons by their inhibitory actions on GABAergic transmission.
As briefly described in the Introduction, patients with Parkinson disease experience severe sleep disturbances, such as light fragmented sleep and abnormal motor activity during sleep, 14 and excessive daytime sleepiness and sleep attacks are common complaints in patients with Parkinson disease who are taking dopaminergic compounds such as Ldopa and D 2 -like DA-receptor agonists 15, 16 ; these patients have been reported to fall asleep while driving as a consequence of sudden irresistible attacks of sleep. 46 At present, the sites of action of these DAreceptor agonists remain unknown. Recent works have reported that the D 2 /D 3 -receptor mechanism is specifically involved in the regulation of cataplexy 47, 48 and suggested that the dopaminergic modulation of sleep and cataplexy is primarily mediated by effects on the presynaptic receptors located on DA neurons in the ventral tegmental area. 49, 50 Our present findings suggest that the dorsal pontine tegmentum and, in particular, the peri-LCα region may be another major target of antiparkinsonian dopaminergic agents that induce excessive daytime sleepiness and sudden-onset sleep attacks in humans, as well as the target of D 2 /D 3 agonists and antagonists that aggravate or block, respectively, cataplexy in canine narcolepsy.
